{"id":"W3043096450","doi":"10.1200/jco.20.00147","title":"Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":609,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Puma Biotechnology; American Society of Clinical Oncology","keywords":"Capecitabine; Medicine; Lapatinib; Internal medicine; Neratinib; Hazard ratio; Metastatic breast cancer; Clinical endpoint; Gastroenterology; Oncology; Cancer; Breast cancer; Trastuzumab; Randomized controlled trial; Confidence interval; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001358796,0.0004933127,0.003960949,0.0002187111,0.00007673886,0.00002204002,0.0002397541,0.0003853433,0.002069716],"category_scores_gemma":[0.001023859,0.0003407793,0.0005676047,0.0007531806,0.0003815321,0.0002109736,0.00005805834,0.001718669,0.00001907635],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001211834,"about_ca_system_score_gemma":0.005768008,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009939742,"about_ca_topic_score_gemma":0.002074658,"domain_scores_codex":[0.9934542,0.001356075,0.003388042,0.0005795839,0.0006018271,0.0006202557],"domain_scores_gemma":[0.9928884,0.00259172,0.002444037,0.0002260292,0.0008374167,0.00101238],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.931025,0.009077248,0.002005802,0.00007192568,0.003665871,0.007380187,0.001416034,0.0003074689,0.0004522916,0.0000147712,0.01328601,0.03129744],"study_design_scores_gemma":[0.8342323,0.134207,0.00591717,0.0003348579,0.004919664,0.000802552,0.0004559378,0.002486312,0.0001967312,0.000006866887,0.01605764,0.0003829632],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9656643,0.0013839,0.00003170907,0.02754411,0.00159347,0.001935205,0.000110983,0.00005839851,0.001677982],"genre_scores_gemma":[0.9867949,0.001693765,0.001649886,0.004570308,0.004246474,0.0001602164,0.00009415246,0.00007688878,0.0007134414],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1251298,"threshold_uncertainty_score":0.9999044,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1286213107058051,"score_gpt":0.467998518340425,"score_spread":0.3393772076346199,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}